Ignite Creation Date:
2024-05-06 @ 6:43 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05765604
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-23
First Post:
2023-03-10
Brief Title:
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine Sf9 Cell WSK-V102
Sponsor:
WestVac Biopharma Co Ltd
Organization:
WestVac Biopharma Co Ltd
Study Overview
Official Title:
A Randomized Parallel Controlled Double-blind Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine Sf9 CellWSK-V102 in People Aged 18 Years or Older
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Subjects aged 18 and above who have been completed primary or booster vaccination of COVID-19 inactivated vaccines for 3 months or more to conduct a randomized parallel controlled double-blind single-center phase I clinical trial of Recombinant variant COVID-19 vaccine Sf9 cellWSK-V102 to evaluate the safety tolerance and immunogenicity of this vaccine in the study population
Detailed Description:
Low and high doses of study vaccine were compared with control groups to evaluate the safety and immunogenicity of the study vaccine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None